Group items tagged

One hour public information video lecture about vitamin D by professor Reinhold Vieth, Toronto University, Canada.Also a video lecture about nutritional interventions in multiple sclerosis,

Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D.\nRamagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, Deluca GC, Herrera BM, Chao MJ, Sadovnick AD, Ebers GC, Knight JC.\nPLoS Genet. 2009 Feb;5(2):e1000369. Epub 2009 Feb 6.\nPMID: 19197344 [

Supplements of vitamin D at 'critical time periods' may be key to reducing the risk of multiple sclerosis, according to a new study from the UK and Canada. Researchers report that vitamin D may interact with a specific genetic component called HLA-DRB1*1501 that is known to increase the risk of multiple sclerosis by three-fold

"Posted Tue Nov 17, 2009 4:01pm AEDT Updated Tue Nov 17, 2009 4:27pm AEDT Researchers are advising people with MS to take safe levels of vitamin D supplements. Researchers are advising people with MS to take safe levels of vitamin D supplements. (ABC News: Giulio Saggin, file photo) * Audio: New research shows Vitamin D may slow the progress of MS (The World Today) Australian scientists have found that Vitamin D may slow the progression of multiple sclerosis (MS). Figures showing that people living in Tasmania are seven times more likely to develop MS than Queenslanders had suggested a link between sunlight exposure and the disease. "

"Powerful new evidence about the ability of vitamin D to stem a wide range of diseases has brought the prospect of a nationwide programme to prescribe it in Scotland as a dietary supplement significantly closer. Reports at the weekend suggested that experts were increasingly convinced that the so-called sunshine drug - whose significance was first revealed in detail by The Times last year - could make a difference to the country's appalling health record. New research suggests that high doses of vitamin D could dramatically cut the relapse rate in people with multiple sclerosis. According to scientists in Canada, more than a third of sufferers taking high levels of supplement

Multiple Sclerosis Blog By Julie Stachowiak, Ph.D.,

"April 28, 2009 (Seattle) -- High doses of vitamin D dramatically cut the relapse rate in people with multiple sclerosis, a study shows. Sixteen percent of 25 people with multiple sclerosis (MS) given an average of 14,000 international units (IU) of vitamin D a day for a year suffered relapses, says Jodie Burton, MD, a neurologist at the University of Toronto. In contrast, close to 40% of 24 MS patients who took an average of 1,000 IU a day -- the amount recommended by many MS specialists -- relapsed, she says. Also, people taking high-dose vitamin D suffered 41% fewer relapses than the year before the study began, compared with 17% of those taking typical doses. People taking high doses of vitamin D did not suffer any significant side effects, Burton tells WebMD."

"Dr. Jodie Burton is the acting principal investigator (PI) of the dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis with Dr. O'Connor. She started the trial as his fellow, while doing an additional 2 years of training in MS specifically after she received her neurology certification. She completed her fellowship training in 2007. Now she is staff doing clinical research and continuing with the vitamin D trial. As of August 2009, she will be Assistant Professor in Neurology in the Department of Clinical Neuroscience in Calgary and at the University of Calgary. She will be part of the MS team there with Dr. Luanne Metz and the MS group. Please scroll down for an abstract of the trial: A Phase I/II dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis." Conclusions: High-dose VD3 (~10 000 IU/day, possibly higher) in MS is safe and tolerable, with evidence of clinical improvement."

"In 1995 my son received the devastating diagnosis of MS. Having been a research scientist for 30 years, I decided to plunge into the scientific literature for MS to determine the most likely factors which cause MS and to use this information to develop an effective therapy for my son. Notably, many people are having great success in halting or greatly slowing MS with nutritional strategies; many Testimonials are available. I am most pleased to report that my son remains in excellent health with no MS symptoms. I discovered abundant scientific evidence that indicates that various nutritional factors potentially play major roles in the onset and progression of MS. Strangely, this information was not being made available to persons with MS by doctors nor by established MS charities."

Professor Departments of Nutritional Sciences, Laboratory Medicine, and Pathobiology, Bone and Mineral Laboratory, Pathology and Laboratory Medicine, University of Toronto, Toronto, Canada M5S 3E2 Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada

"This website is about Vitamin D and MS Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), with an uncertain cause. Colleen Hayes and Donald Achaeson have suggested that insufficient sunlight exposure and chronic viral infections might be unrelated environmental risk factors for MS. These risk factors may act synergistically to enable the pathogenic autoimmune response. The prevalence of MS is highest where environmental supplies of vitamin D are lowest. Sunshine enables the production of vitamin D3 (VD3) in the skin. Epidemiological studies have shown that higher vitamin D blood levels are associated with lower risk, less relapses and a slower progression of multiple sclerosis. Higher vitamin D levels can be achieved in part by increased oral intake of VD3. Optimal health requires serum 25 hydroxyvitamin D levels higher than 20 ng/ml (50 nmol/L) P Lips, 40 ng/ml (100 nmol/L) P Heaney or at least 40 ng/ml (100 nmol/L) R Vieth. "

Safety of vitamin D3 in adults with multiple sclerosis. Kimball SM, Ursell MR, O'Connor P, Vieth R. Am J Clin Nutr. 2007 Sep;86(3):645-51. PMID: 17823429 Conclusions: Patients' serum 25(OH)D concentrations reached twice the top of the physiologic range without eliciting hypercalcemia or hypercalciuria. The data support the feasibility of pharmacologic doses of vitamin D3 for clinical research, and they provide objective evidence that vitamin D intake beyond the current upper limit is safe by a large margin.